InnoPharmax Inc. (TPEX:4172)

InnoPharmax Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	185.79	97.28	166.73	39.36	40.53	90.51
Short-Term Investments	69.4	49	114.5	100.3	55.85	96.76
Cash & Short-Term Investments	255.19	146.28	281.23	139.66	96.37	187.26
Cash Growth	4.77%	-47.98%	101.37%	44.91%	-48.54%	-22.58%
Accounts Receivable	6.85	1.83	4.53	6.96	-	-
Other Receivables	0.64	0.89	0.47	0.82	0.57	4.03
Receivables	7.49	2.72	5	7.78	0.57	4.03
Inventory	7.9	15.12	18.34	25.53	30.5	16.12
Prepaid Expenses	4.41	2.8	2.46	3.38	1.1	1.92
Other Current Assets	8.58	8.58	13.26	12.65	8.2	-
Total Current Assets	283.57	175.51	320.29	188.99	136.74	209.33
Property, Plant & Equipment	14.35	3.42	8.59	13.77	19.57	13.77
Long-Term Investments	245.08	251.32	261.21	269.14	278.43	283.97
Other Intangible Assets	4.9	5.27	6.22	6.72	8.85	9.75
Long-Term Accounts Receivable	-	-	-	6.09	6.09	6.09
Long-Term Deferred Tax Assets	15.89	15.89	19.4	21.72	21.72	21.72
Other Long-Term Assets	17.55	17.58	17.35	17.75	17.92	11.53
Total Assets	581.33	468.98	633.06	524.2	489.31	556.16

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	8.32	9.57	2.4	6.7	0.84	0.84
Accrued Expenses	24.91	24.07	8.57	0	0.23	0.04
Short-Term Debt	-	10	10	11.5	23.27	-
Current Portion of Leases	4.36	0.82	4.57	4.48	4.42	4.5
Current Unearned Revenue	2.7	3.64	2.44	0.18	0.18	0.18
Other Current Liabilities	3.89	1.71	1.41	11.09	10.19	8.66
Total Current Liabilities	44.18	49.81	29.4	33.95	39.13	14.22
Long-Term Leases	7.44	-	0.82	5.39	9.86	1.08
Other Long-Term Liabilities	-	-	-	9.32	9.32	9.32
Total Liabilities	51.61	49.81	30.22	48.65	58.31	24.61

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	1,196	1,076	1,076	949.97	868.36	867.19
Additional Paid-In Capital	160.43	100.43	100.43	34.17	0.77	52.86
Retained Earnings	-826.47	-757.01	-572.96	-507.84	-437.48	-386.89
Comprehensive Income & Other	-	-	-0.44	-0.75	-0.66	-1.61
Shareholders' Equity	529.72	419.18	602.85	475.55	431	531.54
Total Liabilities & Equity	581.33	468.98	633.06	524.2	489.31	556.16

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	11.8	10.82	15.39	21.36	37.56	5.57
Net Cash (Debt)	243.39	135.46	265.84	118.29	58.82	181.69
Net Cash Growth	8.68%	-49.04%	124.73%	101.12%	-67.63%	-14.29%
Net Cash Per Share	2.18	1.26	2.73	1.28	0.68	2.10
Filing Date Shares Outstanding	119.58	107.58	107.58	95	86.84	86.72
Total Common Shares Outstanding	119.58	107.58	107.58	95	86.84	86.72
Working Capital	239.39	125.7	290.89	155.05	97.61	195.11
Book Value Per Share	4.43	3.90	5.60	5.01	4.96	6.13
Tangible Book Value	524.82	413.91	596.62	468.82	422.15	521.8
Tangible Book Value Per Share	4.39	3.85	5.55	4.94	4.86	6.02
Machinery	36.31	35.94	35.67	35.14	34.74	36.97
Leasehold Improvements	0.66	0.66	0.66	0.66	0.66	0.66

Data Source: S&P Global Market Intelligence Last updated: Aug 13, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 5, 2026

Data Sources Report a data error